Thus, EZH2 is an important player in prostate cancer initiation, progression, and therapeutic response, owing partially to its role in modulating the epigenomic landscape and ensuing tumor transcriptome via its catalytic methyltransferase function (Figure 2). This evidence concerns the gene EZH2 and Familial prostate cancer.